Table 1.
A.1 | Reference range* | |
---|---|---|
CD4:CD8 ratio | 1.46–3.54 | 0.74–5.17 |
CD4+ T cells |
427–795/μL 37.3–58.9% |
358–1565/μL 27.0–62.2% |
CD8+ T cells |
132–342/μL ↓ 16.5–25.5% ↓ |
149–911/μL 11.2–50.8% |
CD8+ central memory (CD62L+ CD45RA−) |
14–38/μL ↓ 1.5–5.5% |
25–180/μL 1.5–10.3% |
CD8+ effector memory (CD62L− CD45RA−) |
4–9/μL ↓ 0.4–1.3% ↓ |
24–175/μL 1.1–9.2% |
CD8+ Temra (CD62− CD45RA+) |
4–6/μL ↓ 0.6–0.6% ↓ |
11–172/μL 0.7–7.8% |
CD4+ CD25+ T cells |
114–224/μL ↓ 11.3–18.9% ↓ |
139–1223/μL 10.6–41.2% |
DNαβT cells (CD4− CD8− TCRα/β+) |
14–32/μL ↑ 1.3–3.0% ↑ |
2–23/μL 0.1–1.3% |
γδT cells (TCRγ/δ+) |
22–145/μL 2.2–11.5% ↑ |
5–261/μL 0.3–10.4% |
CD4 + HLA-DR + T cells |
20–115/μL ↑ 1.5–11.4% ↑ |
0–139/μL 0.0–6.8% |
NK cells (CD56+ CD16+) |
30–131/μL ↓ 2.9–12.9% ↓ |
87–729/μL 4.6–34.6% |
Memory B cells** (CD20+ CD27+) |
0–17/μL ↓ 0.0–1.5% ↓ |
12–118/μL 0.7–6.3% |
IgG, serum*** | 294–413 ↓ | 549–1584 mg/dL |
IgA, serum | 15–33 ↓ | 45–359 mg/dL |
IgM, serum | 26–88 ↓ | 23–259 mg/dL |
Neutrophils |
1.18–6.96 K/μL ↓↑ 49.6–81.5% ↑ |
1.56–7.87 K/μL 29.8–77.0% |
Eosinophils |
0.043–0.570 K/μL ↑ 0.6–9.2% ↓↑ |
0.03–0.47 K/μL 0.0–7.0% |
Monocytes |
0.15–0.40 K/μL ↓ 3.5–10.5% ↓ |
0.19–0.86 K/μL 4.2–12.5% |
A minimum of three tests from independent blood draws are included for each row. Percentages indicate % of lymphocytes for lymphocyte populations and % of leukocytes for non-lymphocyte populations.
*Listed ranges reflect the aggregate of ranges used by the NIH Clinical Center for each age (as established at the time of testing) at which blood draws from patient A.1 are included. In some instances, lab values fall outside the corresponding age-matched reference range but do not fall outside the aggregate range.
**Prior to receiving rituximab.
***Prior to receiving IVIG